Eisai R&d Management Co., Ltd.

Masayuki Miyano

John JianShi Wang

Guo Zhu Zheng

Yoshihiko Kotake

Gregg F Keaney

Kazunobu Kira

Parcharee Tivitmahaisoon

Sudeep Prajapati

Norio Murai

Baudouin Gerard

Xiang Liu

Satoshi Nagao

Regina Mikie Kanada Sonobe

Nicholas C Gearhart

Kenzo Arai

Atsushi Endo

Peter G Smith

Silvia Buonamici

Lihua Yu

Ermira Pazolli

Eunice Sun Park

Kian Huat Lim

Michael P Thomas

Betty Chan

Keigo Tanaka

Ming-Hong Hao

Dominic J Reynolds

Andrew Cook

Arani Chanda

Jason T Lowe

James Palacino

Tasuku Ishida

Shelby Ellery

Lisa A Marcaurelle

Raku Shinkyo

Morgan Welzel O'shea

Tuoping Luo

Regina Mikie Kanada Sonabe

Regina Kanada Sonobe

Sundeep Prajapati

The present disclosure provides novel pladienolide compounds, pharmaceutical compositions containing such compounds, and methods for using the compounds as therapeutic agents. These compounds may be useful in the treatment of cancers, particularly cancers in which agents that target the spliceosome and mutations therein are known to be useful. Also provided herein are methods of treating cancers by administering at least one compound disclosed herein and at least one additional therapy.

Certain pladienolide compounds and methods of use

The present disclosure provides a novel solid state form of pladienolide pyridine compounds having Formula I, compositions comprising at least one such solid state form, and methods of preparation and use and the same. The novel solid state form of pladienolide pyridine compounds may be useful in the treatment of cancer, such as, for example, cancers in which agents that target the spliceosome and mutations therein are known to be useful. 

Crystalline form of (2S,3S,6S,7R,10R,E)-7,10-dihydroxy-3,7-dimethyl-12-oxo-2-((R,2E,4E)-6-(piridin-2-yl)hepta-2,4-dien-2-yl)oxacyclododec-4-en-6-yl-4-methylpiperazine-1-carboxylate and methods of use thereof

The present invention provides a compound represented by formula (1): or pharmaceutically acceptable salt thereof, wherein

ALDH2 activator

The present invention provides novel pladienolide pyridine compounds, pharmaceutical compositions containing such compounds, and methods for using the compounds as therapeutic agents. These compounds may be useful in the treatment of cancer, particularly cancers in which agents that target the spliceosome and mutations therein are known to be useful.

Pladienolide pyridine compounds and methods of use

Growing community of inventors

Tsukuba, Japan

Masayuki Miyano